Efficacy and Safety of Dacomitinib in the Treatment of Skin Squamous Cell Cancer

Inclusion Criteria: * Signed informed consent to treatment * Histological diagnosis of squamous cell carcinoma of the skin not amenable to surgical treatment with curative purposes or with clinical contraindication to surgery (examples of medical contraindications to surgery include but are not limited to: skin SCC that has recurred in the same location after two or more surgical procedures and curative resection is deemed unlikely; anticipated substantial morbidity and/or deformity from surgery (e.g., removal of all or part of a facial structure, such as nose, ear, eyelid, eye; or requirement for limb amputation); anticipated difficulty in obtaining a curative resection due to the location of the tumour, the size of disease; anticipated difficulty in reconstructing the area that will be surgically removed; significant comorbidities that preclude the feasibility of a radical surgery * Presence of measurable disease according to RECIST 1.1 * ECOG performance status 0-2 * Age≥ 18 years * For men and women in the fertile period: the use of birth control systems during treatment Exclusion Criteria: * Previous treatment with tyrosine kinase inhibitors or monoclonal antibodies directed against EGFR * Any toxicity CTC grade\> 2 from previous treatments not yet resolved * Pregnant or breastfeeding